The Union Health Ministry has amended the NDCT Rules, 2019 to reduce regulatory burden, waive permissions for low-risk ...
A top federal health official is again touting the therapeutic “promise” of psychedelics such as psilocybin and MDMA—though ...
Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.
The collaboration marks a turning point in AI-driven drug design and trial forecasting, de-risking the drug development ...
GlobalData on MSN
FDA and EMA release collaborative AI framework for drug development
The joint guidance was created to ensure drug developers employ best practices when using AI.
Jan 14 (Reuters) - The U.S. Food and Drug Administration and the European Medicines Agency jointly issued principles for safe ...
The FDA granted orphan drug designation to zavabresib, an investigational therapy for the treatment of myelofibrosis, a rare ...
The Brighterside of News on MSN
Scientists map a road to fairer, more inclusive drug development
A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...
Lantern showcases two commercially ready, machine learning platforms that have the potential to accelerate drug discovery from months to days and dramatically reduce costs. predictBBB.ai and LBx-AI, ...
SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate ...
The Nature Index tracks primary research articles from 145 natural-science and health-science journals, chosen based on reputation by an independent group of researchers. The Nature Index provides ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results